ZYGEL
Dead / Abandoned — Abandoned — no statement of use filed (as of 11 Sept 2023)
What this means for you
This application is over — abandoned 11 Sept 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88291596
- Mark type
- Design + words
- Filed
- 06 Feb 2019
- Published for opposition
- 16 Jun 2020
- Abandoned
- 11 Sept 2023
- Attorney of record
- Sarah Anne Keefe
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of human and veterinary diseases and disorders, namely, addiction, auditory diseases and disorders, autism, autoimmune diseases and disorders, anxiety, bone diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, cognitive diseases and disorders, dermatological diseases and disorders, diabetic diseases and disorders, endocrine diseases and disorders, gastroenterological diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hepatological diseases and disorders, hormonal diseases and disorders, infectious diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, metabolic diseases and disorders, movement diseases and disorders, muscular diseases and disorders, musculoskeletal diseases and disorders, neurodegenerative diseases and disorders, neurodevelopmental diseases and disorders, oncological diseases and disorders, ophthalmic diseases and disorders, pain, post-traumatic stress, pulmonary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, rheumatological diseases and disorders, psychiatric diseases and disorders, seizure diseases and disorders, sexual dysfunction, speech disorders and diseases, traumatic brain injury, and viral diseases and disorders; Pharmaceutical preparations for the treatment of fragile x syndrome, substance related addiction, autism and autism spectrum disorders, epilepsy, seizure diseases and disorders, anxiety, aphasias, stuttering, post-traumatic stress disorder; all of the foregoing specifically excluding narcolepsy and management of sleep disorders and all of the foregoing solely derived from manufactured synthetic cannabidiol and which do not contain delta-9 tetrahydrocannabinol (THC)
Owner
- Zynerba Pharmaceuticals, Inc., Devon, PA, US
- Zynerba Pharmaceuticals, Inc., Devon, PA, US
Prosecution history
- 11 Sept 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 11 Sept 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 23 Feb 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Feb 2023 — SOU EXTENSION 5 GRANTED
- 06 Feb 2023 — SOU EXTENSION 5 FILED
- 22 Feb 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 06 Feb 2023 — SOU TEAS EXTENSION RECEIVED
- 28 Jun 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jun 2022 — SOU EXTENSION 4 GRANTED
- 24 Jun 2022 — SOU EXTENSION 4 FILED
- 24 Jun 2022 — SOU TEAS EXTENSION RECEIVED
- 08 Feb 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Feb 2022 — SOU EXTENSION 3 GRANTED
- 04 Feb 2022 — SOU EXTENSION 3 FILED
- 04 Feb 2022 — SOU TEAS EXTENSION RECEIVED